Apimeds Pharmaceuticals US, Inc. (APUS) company profile

Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on the development of Apitox, an intradermally administered purified honeybee venom-based biologic. The company develops therapies designed to treat inflammation and manage pain symptoms associated with knee osteoarthritis and multiple sclerosis. Operating through wholly owned subsidiaries Lokahi Therapeutics, Inc. and MindWave Innovations Inc., the business directs its offerings toward clinical patient populations suffering from chronic inflammatory and neurodegenerative joint or central nervous system disorders. Additionally, through educational initiatives such as the ai² Futures Lab, the organization collaborates with university students to evaluate therapeutic assets.

The company focuses its primary clinical development activities within the United States. Its operations rely on prior clinical trial data and proprietary extraction methods established in South Korea. The company maintains its principal executive offices in Matawan, New Jersey.

Summary of the business section of Apimeds Pharmaceuticals US's latest annual report, written by StockData.

“Per Share Total Initial public offering price $ 4.00 $ 13,500,000 Underwriting discounts and commissions (1) $ 0.28 $ 945,000 Proceeds to us, before expenses $ 3.72 $ 12,555,000 ____________ (1) Underwriting discounts and commissions do not include a non -accountable expense allowance equal to 1.0% of the initial p”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of January 11, 2026, we had a total of 9 employees,”